CA3165738A1 - Treatment of mild traumatic brain injury - Google Patents

Treatment of mild traumatic brain injury

Info

Publication number
CA3165738A1
CA3165738A1 CA3165738A CA3165738A CA3165738A1 CA 3165738 A1 CA3165738 A1 CA 3165738A1 CA 3165738 A CA3165738 A CA 3165738A CA 3165738 A CA3165738 A CA 3165738A CA 3165738 A1 CA3165738 A1 CA 3165738A1
Authority
CA
Canada
Prior art keywords
ghrelin
variant
days
mtbi
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3165738A
Other languages
English (en)
French (fr)
Inventor
Vishal Bansal
Kartik Shah
Michael Wyand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxeia Biopharmaceuticals Inc
Original Assignee
Oxeia Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxeia Biopharmaceuticals Inc filed Critical Oxeia Biopharmaceuticals Inc
Publication of CA3165738A1 publication Critical patent/CA3165738A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3165738A 2019-12-23 2020-12-22 Treatment of mild traumatic brain injury Pending CA3165738A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953130P 2019-12-23 2019-12-23
US62/953,130 2019-12-23
PCT/US2020/066703 WO2021133844A1 (en) 2019-12-23 2020-12-22 Treatment of mild traumatic brain injury

Publications (1)

Publication Number Publication Date
CA3165738A1 true CA3165738A1 (en) 2021-07-01

Family

ID=76575665

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3165738A Pending CA3165738A1 (en) 2019-12-23 2020-12-22 Treatment of mild traumatic brain injury

Country Status (11)

Country Link
US (1) US20230031262A1 (https=)
EP (1) EP4081238A4 (https=)
JP (1) JP2023508250A (https=)
KR (1) KR20220122691A (https=)
CN (1) CN114980915A (https=)
AU (1) AU2020412765A1 (https=)
BR (1) BR112022012365A2 (https=)
CA (1) CA3165738A1 (https=)
IL (1) IL294156A (https=)
MX (1) MX2022007844A (https=)
WO (1) WO2021133844A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370804A1 (en) * 2021-01-22 2022-11-24 The Regents Of The University Of Colorado, A Body Corporate Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders
CN113723530B (zh) * 2021-09-02 2022-03-25 中国科学院自动化研究所 基于视频分析和电子心理沙盘的智能心理评估系统
AU2023338304A1 (en) * 2022-09-07 2025-04-10 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6545697B2 (ja) * 2013-11-15 2019-07-17 ニューラル・アナリティクス・インコーポレーテッド 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること
US9119832B2 (en) * 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
AU2015305647A1 (en) * 2014-08-19 2017-04-06 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
WO2016134215A1 (en) * 2015-02-19 2016-08-25 The Regents Of The University Of California Methods of treating mild brain injury and post-traumatic stress disorder
US20180071367A1 (en) * 2015-03-09 2018-03-15 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Also Published As

Publication number Publication date
BR112022012365A2 (pt) 2022-08-30
CN114980915A (zh) 2022-08-30
JP2023508250A (ja) 2023-03-01
US20230031262A1 (en) 2023-02-02
AU2020412765A1 (en) 2022-07-14
WO2021133844A1 (en) 2021-07-01
EP4081238A4 (en) 2023-08-30
EP4081238A1 (en) 2022-11-02
MX2022007844A (es) 2022-09-07
IL294156A (en) 2022-08-01
KR20220122691A (ko) 2022-09-02

Similar Documents

Publication Publication Date Title
Reich et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial
Obermann et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial
Friedman et al. Diazepam is no better than placebo when added to naproxen for acute low back pain
Ferguson et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
Bleecker et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
McGuinness et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia
Steiner et al. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study
Brown et al. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial
Feil et al. Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial
CA3165738A1 (en) Treatment of mild traumatic brain injury
Dart et al. The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F (abʹ) 2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
Rose et al. Treatment for inclusion body myositis
Pearlman et al. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6–< 12 years)
Smith et al. Safety and efficacy of topiramate in individuals with cryptogenic sensory peripheral neuropathy with metabolic syndrome: the TopCSPN randomized clinical trial
US20260077018A1 (en) Treatment of mild traumatic brain injury
Wolstein et al. A randomized, open-label trial comparing methadone and levo-alpha-acetylmethadol (LAAM) in maintenance treatment of opioid addiction
Attallah et al. Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis
Stempel et al. Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast
HK40080092A (en) Treatment of mild traumatic brain injury
Manti et al. Efficacy and perceived satisfaction of 3-year SLIT in children with allergic rhinitis and asthma: A pilot study in real-life.
Khokhar et al. Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy
Pérez-Garrigues et al. Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study
Hale et al. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended‐Release Hydrocodone Tablet Formulated with Abuse‐Deterrence Technology: A 12‐month Open‐label Study in Patients with Chronic Pain
Kibleur et al. French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS® in MDR-TB Patients
AU2024230473A1 (en) Compositions and methods for treating charcot–marie–tooth disease

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241205

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226